Advisor Group Holdings Inc. acquired a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 23,772 shares of the company’s stock, valued at approximately $61,000. Advisor Group Holdings Inc. owned approximately 0.09% of AIM ImmunoTech at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AIM. Jane Street Group LLC acquired a new position in AIM ImmunoTech in the 1st quarter valued at $72,000. Morgan Stanley increased its stake in shares of AIM ImmunoTech by 23,782.9% in the 1st quarter. Morgan Stanley now owns 18,151 shares of the company’s stock valued at $46,000 after purchasing an additional 18,075 shares during the last quarter. Finally, Traynor Capital Management Inc. bought a new position in shares of AIM ImmunoTech in the 1st quarter valued at $30,000. 1.74% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on AIM shares. Maxim Group lifted their price target on AIM ImmunoTech from $2.00 to $5.00 in a research note on Monday, April 6th. TD Securities lifted their price target on AIM ImmunoTech from $3.25 to $4.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th.
NYSE AIM opened at $2.92 on Friday. The business’s 50-day moving average price is $2.70 and its two-hundred day moving average price is $2.16. AIM ImmunoTech Inc. has a 12 month low of $0.38 and a 12 month high of $7.11. The company has a current ratio of 42.26, a quick ratio of 42.26 and a debt-to-equity ratio of 0.19.
AIM ImmunoTech (NYSE:AIM) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.12). The company had revenue of $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 5,392.43% and a negative return on equity of 61.52%.
AIM ImmunoTech Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading: What member countries make up the G-20?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.